Identifying novel strategies for treating human hair loss disorders: Cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles
Fig 3
Inhibiting SFRP1 activity with WAY-316606 enhances human hair growth, increases K85 protein expression, and inhibits spontaneous catagen ex vivo.
(A) Hair shaft elongation of human HFs ex vivo with WAY-316606 treatment (n = 31 HFs Control, 30 HFs WAY-316606; from 3 male patient samples). (B) K85 protein quantification using immunofluorescence after 48 hours of treatment with WAY-316606 (n = 16 HFs control, 14 HFs WAY-316606; from 3 male patient samples). (C) Macroscopic quantification of hair cycle stage on day 6 with WAY-316606 treatment. (D–H) Validation of HF cycle stage with Ki-67/TUNEL analysis (n = 21 HFs control, 20 HFs WAY-316606; from 3 male patient samples) and Masson's-Fontana (n = 17 HFs control, 20 HFs WAY-316606; from 3 male patient samples). (I) Working hypothesis. Data are expressed as mean ± SEM. (A, B, E, G, and H) Two-tailed unpaired t test and (F) Mann-Whitney test. Scale bars, A = 1 mm; B, D, and H = 50 μm. Underlying data can be found in S1 Data. AL, Auber’s line; Axin2, axis inhibition protein 2; CsA, Cyclosporine A; DC, differentiating cell; DP, dermal papilla; DPC, dermal papilla cell; HF, hair follicle; K85, Keratin 85; LEF1, lymphoid enhancer binding factor 1; SFRP1, secreted frizzled related protein 1; TAC, transient amplifying cell; WAY, WAY-316606.